Genome-wide association study reveals targets for COVID-19 treatments
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
List view / Grid view
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
Researchers have been tracking SARS-CoV-2 by sequencing the genomes of virus samples collected from diagnostic testing. They hope that using next-generation sequencing (NGS) on SARS-CoV-2 will help to accurately diagnose the novel coronavirus, identify mutations and track its history. This article explores the findings of their latest study and what…
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.